Hybrid Methacrylated Gelatin and Hyaluronic Acid Hydrogel Scaffolds. Preparation and Systematic Characterization for Prospective Tissue Engineering Applications.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
23 Jun 2021
Historique:
received: 14 05 2021
revised: 17 06 2021
accepted: 19 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 27 7 2021
Statut: epublish

Résumé

Hyaluronic acid (HA) and gelatin (Gel) are major components of the extracellular matrix of different tissues, and thus are largely appealing for the construction of hybrid hydrogels to combine the favorable characteristics of each biopolymer, such as the gel adhesiveness of Gel and the better mechanical strength of HA, respectively. However, despite previous studies conducted so far, the relationship between composition and scaffold structure and physico-chemical properties has not been completely and systematically established. In this work, pure and hybrid hydrogels of methacroyl-modified HA (HAMA) and Gel (GelMA) were prepared by UV photopolymerization and an extensive characterization was done to elucidate such correlations. Methacrylation degrees of ca. 40% and 11% for GelMA and HAMA, respectively, were obtained, which allows to improve the hydrogels' mechanical properties. Hybrid GelMA/HAMA hydrogels were stiffer, with elastic modulus up to ca. 30 kPa, and porous (up to 91%) compared with pure GelMA ones at similar GelMA concentrations thanks to the interaction between HAMA and GelMA chains in the polymeric matrix. The progressive presence of HAMA gave rise to scaffolds with more disorganized, stiffer, and less porous structures owing to the net increase of mass in the hydrogel compositions. HAMA also made hybrid hydrogels more swellable and resistant to collagenase biodegradation. Hence, the suitable choice of polymeric composition allows to regulate the hydrogels´ physical properties to look for the most optimal characteristics required for the intended tissue engineering application.

Identifiants

pubmed: 34201769
pii: ijms22136758
doi: 10.3390/ijms22136758
pmc: PMC8268476
pii:
doi:

Substances chimiques

Biocompatible Materials 0
Hydrogels 0
Methacrylates 0
Polymers 0
Gelatin 9000-70-8
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agencia Estatal de Investigación
ID : PID2019-109517RB-I00,
Organisme : Agencia Estatal de Investigación
ID : MAT2016-8266R
Organisme : Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia
ID : ED431C 2018/26
Organisme : Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia
ID : ED431C 2020/17
Organisme : International Scientific Partnership Program ISSP at King Saud University
ID : ISPP-144

Références

PLoS One. 2017 Jun 6;12(6):e0177628
pubmed: 28586346
Biomaterials. 2005 May;26(15):2517-25
pubmed: 15585254
Int J Oncol. 2009 Oct;35(4):761-73
pubmed: 19724912
Biomed Res Int. 2014;2014:786892
pubmed: 24804246
Macromol Biosci. 2009 Jan 9;9(1):20-8
pubmed: 18839402
Biomaterials. 2009 Oct;30(29):5270-8
pubmed: 19592087
Biomaterials. 2006 Mar;27(8):1362-76
pubmed: 16174523
Biomaterials. 2010 Jan;31(3):461-6
pubmed: 19819008
Cardiovasc Res. 1999 Feb;41(2):395-401
pubmed: 10341839
Biomaterials. 2015 Jan;37:174-82
pubmed: 25453948
ACS Appl Mater Interfaces. 2016 Aug 31;8(34):22005-17
pubmed: 27494432
Tissue Eng Part A. 2009 Nov;15(11):3221-30
pubmed: 19374488
Int J Artif Organs. 2011 Feb;34(2):93-102
pubmed: 21374568
Int J Biol Macromol. 2011 Apr 1;48(3):474-81
pubmed: 21255605
Dermatoendocrinol. 2012 Jul 1;4(3):253-8
pubmed: 23467280
Biomacromolecules. 2013 Apr 8;14(4):1085-92
pubmed: 23419055
Biomacromolecules. 2018 Jan 8;19(1):42-52
pubmed: 29211461
AAPS J. 2005 Sep 02;7(1):E231-40
pubmed: 16146344
Biomaterials. 2008 Apr;29(12):1739-49
pubmed: 18234331
Biomacromolecules. 2000 Spring;1(1):31-8
pubmed: 11709840
Mater Sci Eng C Mater Biol Appl. 2013 Oct;33(7):3958-67
pubmed: 23910302
FASEB J. 2006 May;20(7):811-27
pubmed: 16675838
Biomaterials. 2017 Jun;129:188-198
pubmed: 28343005
Colloids Surf B Biointerfaces. 2013 Feb 1;102:405-11
pubmed: 23010124
Regen Biomater. 2020 Mar;7(2):195-202
pubmed: 32296538
J Control Release. 2005 Jan 20;102(1):13-22
pubmed: 15653130
J Mater Sci Mater Med. 2009 Jun;20(6):1263-71
pubmed: 19184370
Adv Healthc Mater. 2015 Jan 7;4(1):121-30
pubmed: 24958085
J Mater Sci Mater Med. 2018 Jun 14;29(6):88
pubmed: 29904797
Biomaterials. 2010 Jul;31(21):5536-44
pubmed: 20417964
Sci Rep. 2019 Jul 22;9(1):10542
pubmed: 31332239
Carbohydr Polym. 2016 May 5;141:175-83
pubmed: 26877010
Biotechnol Bioeng. 2009 Jul 1;103(4):655-63
pubmed: 19472329
Biomaterials. 2006 Dec;27(35):5909-17
pubmed: 16949666
Biomaterials. 2013 Dec;34(38):10143-50
pubmed: 24075410
ACS Biomater Sci Eng. 2021 Feb 8;7(2):383-399
pubmed: 33492125
Front Vet Sci. 2019 Jun 25;6:192
pubmed: 31294035
Nat Protoc. 2016 Apr;11(4):727-46
pubmed: 26985572
Cell. 2006 Aug 25;126(4):677-89
pubmed: 16923388
J Clin Neurosci. 2000 Jul;7(4):280-90
pubmed: 10938601
Acta Biomater. 2014 Jan;10(1):214-23
pubmed: 24140603
Materials (Basel). 2014 Apr 17;7(4):3106-3135
pubmed: 28788609
Acta Biomater. 2017 Oct 15;62:42-63
pubmed: 28736220
Acta Biomater. 2017 Mar 15;51:330-340
pubmed: 28110074
Int J Biol Macromol. 2017 Sep;102:885-892
pubmed: 28450250
Int J Biol Macromol. 2017 Apr;97:642-653
pubmed: 28109811
Acta Biomater. 2010 Mar;6(3):1167-77
pubmed: 19733699
Chem Rev. 2001 Jul;101(7):1869-79
pubmed: 11710233
J Tissue Eng Regen Med. 2020 Sep;14(9):1333-1348
pubmed: 32495524
Sci Technol Adv Mater. 2011 Jul 27;12(4):045003
pubmed: 27877422
Adv Healthc Mater. 2017 Jan;6(1):
pubmed: 27900856

Auteurs

B Velasco-Rodriguez (B)

Department of Chemical Engineering, CUCEI, Universidad de Guadalajara, Guadalajara 44430, Mexico.
Colloids and Polymers Physics Group, Department of Particle Physics, Faculty of Physics and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

T Diaz-Vidal (T)

Department of Chemical Engineering, CUCEI, Universidad de Guadalajara, Guadalajara 44430, Mexico.

L C Rosales-Rivera (LC)

Department of Chemical Engineering, CUCEI, Universidad de Guadalajara, Guadalajara 44430, Mexico.

C A García-González (CA)

Department of Pharmacology, Pharmacy and Pharmaceutical Technology, I + D Farma Group (GI-1645), Faculty of Pharmacy and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

C Alvarez-Lorenzo (C)

Department of Pharmacology, Pharmacy and Pharmaceutical Technology, I + D Farma Group (GI-1645), Faculty of Pharmacy and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

A Al-Modlej (A)

Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.

V Domínguez-Arca (V)

Biophysics and Interfaces Group, Department of Applied Physics, Faculty of Physics, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

G Prieto (G)

Biophysics and Interfaces Group, Department of Applied Physics, Faculty of Physics, Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

S Barbosa (S)

Colloids and Polymers Physics Group, Department of Particle Physics, Faculty of Physics and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

J F A Soltero Martínez (JFA)

Department of Chemical Engineering, CUCEI, Universidad de Guadalajara, Guadalajara 44430, Mexico.

P Taboada (P)

Colloids and Polymers Physics Group, Department of Particle Physics, Faculty of Physics and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, E-15782 Santiago de Compostela, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH